SCHEMBL2648404

SCHEMBL2648404

CC(C)(Sc1cnc(NC(=O)N(C2CCCCC2)C2CCC(C(C)(C)C)CC2)s1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
CDK2 P24941 10/20 0.37
CCNE2 O96020 9/20 0.37
CCNE1 P24864 9/20 0.37
CCNB2 O95067 3/20 0.35
CDK1 P06493 3/20 0.35
CDK4 P11802 3/20 0.35
CCNB1 P14635 3/20 0.35
CCND1 P24385 3/20 0.35
CCNB3 Q8WWL7 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 2/20 0.34
CDK9 P50750 3/20 0.33
CIT O14578 1/20 0.33
CASK O14936 1/20 0.33
AURKA O14965 1/20 0.33
GAK O14976 1/20 0.33
DCLK1 O15075 1/20 0.33
MAP3K7 O43318 1/20 0.33
CCNT1 O60563 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648401 1.00 RAB9A (0.43) RAB9ACDK2CCNE2CCNE1CCNB2
SCHEMBL2649005 0.99 RAB9A (0.43) RAB9ACDK2CCNE2CCNE1CCNB2
SCHEMBL2649008 0.99 RAB9A (0.43) RAB9ACDK2CCNE2CCNE1CCNB2
SCHEMBL2649802 0.94 CDK2 (0.41) RAB9ACDK2CCNE2CCNE1CCNB2
SCHEMBL1000423 0.91 CDK2 (0.38) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL1000421 0.91 CDK2 (0.38) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL2647706 0.89 CCNE1 (0.36) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL2648978 0.89 CCNE1 (0.36) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL2647707 0.89 CCNE1 (0.36) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL2648983 0.89 CCNE1 (0.36) CDK2CCNE2CCNE1CCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 RAB9A 2950/4885CDK2 253/4885CCNE2 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.